REAL vs. CRVS
REAL (The RealReal, Inc.) and CRVS (Corvus Pharmaceuticals, Inc.) are both stocks. REAL operates in Specialty Retail (Consumer Cyclical), while CRVS operates in Biotechnology (Healthcare). Over the past 5 years, REAL returned -12.76%/yr vs 33.63%/yr for CRVS. At a 0.26 correlation, their price movements are largely independent.
Performance
REAL vs. CRVS - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, REAL achieves a -34.85% return, which is significantly lower than CRVS's 54.94% return.
REAL
- 1D
- 4.47%
- 1M
- 9.25%
- YTD
- -34.85%
- 6M
- -28.31%
- 1Y
- 92.87%
- 3Y*
- 81.13%
- 5Y*
- -12.76%
- 10Y*
- —
CRVS
- 1D
- 2.84%
- 1M
- -24.68%
- YTD
- 54.94%
- 6M
- 42.53%
- 1Y
- 181.37%
- 3Y*
- 53.32%
- 5Y*
- 33.63%
- 10Y*
- 0.06%
REAL vs. CRVS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
REAL The RealReal, Inc. | -34.85% | 44.37% | 443.78% | 60.80% | -89.23% | -40.58% | 3.66% | -32.68% |
CRVS Corvus Pharmaceuticals, Inc. | 54.94% | 43.93% | 203.98% | 107.06% | -64.73% | -32.30% | -34.56% | 60.47% |
Correlation
The correlation between REAL and CRVS is 0.26, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.26 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.24 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.28 |
Correlation (All Time) Calculated using the full available price history since Jun 28, 2019 | 0.26 |
Fundamentals
REAL:
$3.23B
CRVS:
$1.07B
REAL:
-$0.22
CRVS:
-$0.53
REAL:
$722.53M
CRVS:
$0.00
REAL:
$529.97M
CRVS:
-$26.00K
REAL:
-$60.20M
CRVS:
-$47.43M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
REAL vs. CRVS — Risk / Return Rank
REAL
CRVS
REAL vs. CRVS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for The RealReal, Inc. (REAL) and Corvus Pharmaceuticals, Inc. (CRVS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| REAL | CRVS | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.20 | ||
| Sortino ratioReturn per unit of downside risk | -2.03 | ||
| Omega ratioGain probability vs. loss probability | 1.25 | 1.48 | -0.23 |
| Calmar ratioReturn relative to maximum drawdown | 1.80 | 3.23 | -1.44 |
| Martin ratioReturn relative to average drawdown | 3.95 | 7.03 | -3.08 |
Loading charts...
Drawdowns
REAL vs. CRVS - Drawdown Comparison
The maximum REAL drawdown since its inception was -96.44%, roughly equal to the maximum CRVS drawdown of -96.97%. Use the drawdown chart below to compare losses from any high point for REAL and CRVS.
Loading charts...
Drawdown Indicators
| REAL | CRVS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.44% | -96.97% | +0.53% |
Max Drawdown (1Y)Largest decline over 1 year | -51.95% | -56.43% | +4.48% |
Max Drawdown (3Y)Largest decline over 3 years | -57.16% | -70.50% | +13.34% |
Max Drawdown (5Y)Largest decline over 5 years | -95.42% | -92.40% | -3.02% |
Max Drawdown (10Y)Largest decline over 10 years | — | -96.97% | — |
Current DrawdownCurrent decline from peak | -64.43% | -53.25% | -11.18% |
Average DrawdownAverage peak-to-trough decline | -67.33% | -69.28% | +1.95% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 23.62% | 25.91% | -2.29% |
Volatility
REAL vs. CRVS - Volatility Comparison
The current volatility for The RealReal, Inc. (REAL) is 17.24%, while Corvus Pharmaceuticals, Inc. (CRVS) has a volatility of 23.12%. This indicates that REAL experiences smaller price fluctuations and is considered to be less risky than CRVS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| REAL | CRVS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 17.24% | 23.12% | -5.88% |
Volatility (6M)Calculated over the trailing 6-month period | 48.58% | 111.88% | -63.30% |
Volatility (1Y)Calculated over the trailing 1-year period | 77.43% | 180.64% | -103.21% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 97.37% | 131.02% | -33.65% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 93.85% | 111.13% | -17.28% |
Dividends
REAL vs. CRVS - Dividend Comparison
Neither REAL nor CRVS has paid dividends to shareholders.
Financials
REAL vs. CRVS - Financials Comparison
This section allows you to compare key financial metrics between The RealReal, Inc. and Corvus Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
REAL and CRVS have a correlation of 0.26, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CRVS has higher volatility (23.12%) compared to REAL (17.24%). In terms of maximum drawdown, REAL dropped -96.44% vs CRVS's -96.97%.
REAL currently has the higher Sharpe Ratio (1.21 vs 1.01), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for REAL and CRVS
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer